Mountain Group Capital

Mountain Group Capital, LLC is a Nashville-based venture capital and private equity firm established in 2002. The firm specializes in early-stage investments across various sectors, including life sciences, animal health, and technology. Within life sciences, Mountain Group Capital focuses on areas such as MedTech, medical devices, diagnostics, nutraceuticals, and expedited drug development. In animal health, the firm targets technologies that significantly benefit companion animal health and agricultural practices. Additionally, it invests in disruptive technologies characterized by transformative business models with manageable development risks and expedited market entry. Mountain Group Capital primarily invests in North American companies, particularly in the Southeastern United States and Tennessee, with revenues ranging from $1 million to $50 million. The firm typically seeks minority interests in venture capital investments while aiming for controlling interests in buyouts, adhering to a long-term investment philosophy centered on strong management teams and solid business fundamentals.

Joe Cook III

Managing Director

Joseph C. Cook

Managing Director & Founder

Jay Ferguson

CFO

Rob Readnour

Managing Director

Robin Readnour

Managing Director

Steven D. Singleton

Managing Director

Jack Slaughter

Vice President

Byron Smith

Managing Director

Tyler Whitmore

Vice President

58 past transactions

TARGAN

Series C in 2022
Applied LifeSciences & Systems is a bio-systems company focused on improving animal health and productivity in the poultry, livestock, and aquaculture industries. ALS-S is developing a solution that revolutionizes current vaccination methods. Our technology will detect, target, and deliver vaccines to each and every chick, ensuring effective vaccination. This one-of-a-kind accuracy and consistency in the vaccination process boosts the natural immune response to diseases, improves overall flock health, and provides for a cleaner, healthier chick.

Silicon Ranch

Private Equity Round in 2022
Silicon Ranch Corporation is a Nashville-based company that develops, owns, and operates utility-scale solar power projects. Founded in 2010, the company focuses on delivering reliable and cost-effective solar energy solutions to a variety of clients, including utilities, military installations, and commercial businesses. Silicon Ranch is committed to long-term ownership of its projects, ensuring accountability and support for its partners and the communities it serves. The company also operates a regional energy-training center that provides training in solar installation, maintenance, and weatherization, further contributing to local economic development and job creation. Notable projects include a solar array in Social Circle, Georgia, and a facility at Volkswagen's manufacturing site in Chattanooga, Tennessee.

Circular Genomics

Seed Round in 2021
Circular Genomics is a biotechnology and genomics company that develops RNA-based diagnostic and therapeutic assays to facilitate the treatment of psychiatric and neurological diseases. The company was founded in 2021 and is headquartered in Albuquerque, New Mexico.

TARGAN

Series B in 2021
Applied LifeSciences & Systems is a bio-systems company focused on improving animal health and productivity in the poultry, livestock, and aquaculture industries. ALS-S is developing a solution that revolutionizes current vaccination methods. Our technology will detect, target, and deliver vaccines to each and every chick, ensuring effective vaccination. This one-of-a-kind accuracy and consistency in the vaccination process boosts the natural immune response to diseases, improves overall flock health, and provides for a cleaner, healthier chick.

Mindera Health

Series A in 2021
Mindera Health is a biotechnology company specializing in non-invasive molecular testing devices for skin cancer and other skin diseases. Founded in 2013 and based in Palo Alto, California, the company has developed innovative solutions such as a micro-needle array patch that allows for pain-free and targeted extraction of biomarkers, including RNA, DNA, and proteins, without the need for traditional skin biopsies. Mindera Health focuses on scalable technologies that facilitate the collection and evaluation of genetic data, enabling patients, healthcare professionals, and payers to make informed, data-driven decisions regarding treatment options. The company's advancements in biomarker identification and patient prediction analysis leverage deep learning to optimize treatment plans, particularly for conditions like psoriasis, where the technology helps identify patients best suited for specific biologic therapies.

Advanced Animal Diagnostics

Venture Round in 2021
Advanced Animal Diagnostics, Inc. commercializes proprietary technology for the diagnosis of farm-animal diseases. It uses an animal's own immune response to detect and stage infections to improve the quality of life for producers, processors, animals, and consumers. The company offers QuickSmear, a rapid differential slide to speed and simplify production animal research using differential cell counts; and SCC+ System for early detection of mastitis. Advanced Animal Diagnostics was founded in 2001 and is based in Durham, North Carolina.

Silicon Ranch

Funding Round in 2020
Silicon Ranch Corporation is a Nashville-based company that develops, owns, and operates utility-scale solar power projects. Founded in 2010, the company focuses on delivering reliable and cost-effective solar energy solutions to a variety of clients, including utilities, military installations, and commercial businesses. Silicon Ranch is committed to long-term ownership of its projects, ensuring accountability and support for its partners and the communities it serves. The company also operates a regional energy-training center that provides training in solar installation, maintenance, and weatherization, further contributing to local economic development and job creation. Notable projects include a solar array in Social Circle, Georgia, and a facility at Volkswagen's manufacturing site in Chattanooga, Tennessee.

AN2 Therapeutics

Series A in 2019
AN2 Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of novel medicines targeting infectious diseases. The company focuses on developing a clinical-stage antibacterial compound. It has a strategic partnership with Brii Biosciences. The company was incorporated in 2017 and is based in Menlo Park, California.

TARGAN

Series A in 2019
Applied LifeSciences & Systems is a bio-systems company focused on improving animal health and productivity in the poultry, livestock, and aquaculture industries. ALS-S is developing a solution that revolutionizes current vaccination methods. Our technology will detect, target, and deliver vaccines to each and every chick, ensuring effective vaccination. This one-of-a-kind accuracy and consistency in the vaccination process boosts the natural immune response to diseases, improves overall flock health, and provides for a cleaner, healthier chick.

PhaseBio

Series D in 2018
PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, focused on developing innovative therapies for cardiopulmonary diseases. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor and is currently undergoing Phase III clinical trials for patients experiencing uncontrolled bleeding or requiring urgent surgery. The company is also advancing PB1046, a fusion protein aimed at treating pulmonary arterial hypertension, which is in Phase IIb clinical trials. Additionally, PhaseBio is developing PB6440, an oral agent intended for the treatment of resistant hypertension. Founded in 2002, the company leverages proprietary recombinant biopolymers to enhance the stability and efficacy of its drug candidates.

ORIG3N

Series B in 2018
ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly affecting the heart, liver, and neurodegenerative conditions. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology, enabling the differentiation of cells into any type found in the body. This technology serves multiple purposes, including drug efficacy testing, medication toxicity screening, and facilitating personalized treatment approaches. The company's product offerings include LifeProfiles, a suite of genetic tests such as FITCODE, which provides insights into fitness-related traits; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

Appello Pharmaceuticals

Series A in 2018
Appello Pharmaceuticals, Inc. is a preclinical-stage company based in Nashville, Tennessee, specializing in the development of innovative positive allosteric modulators of mGlu4. These compounds are being investigated for their potential in treating Parkinson’s disease. The company aims to advance its research to provide new therapeutic options for this neurological disorder.

NeuroTronik

Series B in 2017
NeuroTronik, spun out of medical technology incubator Synecor, is developing a medical device that could take the place of drugs currently used to heart failure. Read more about the company's technology,

Boragen

Series A in 2017
Boragen Inc. is a biotechnology company based in Durham, North Carolina, that specializes in designing and developing multifunctional small molecule boron solutions for applications in crop protection, animal health, and human health. Founded in 2015, the company focuses on creating next-generation fungicides through its synthetic chemistry platforms, which aim to promote sustainable farming practices. Boragen's product pipeline includes BAG8, a boron-based multisite fungicide, and BN2266, which targets mRNA processing as a crop protection fungicide. Additionally, the company is developing a dual-function nematicide-fungicide designed for root protection and endo-parasiticides that address resistance challenges. Through its innovative approach, Boragen seeks to enhance agricultural efficiency while minimizing chemical usage.

G1 Therapeutics

Series C in 2016
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. Founded in 2008, the company is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics is advancing several investigational therapies, including trilaciclib, an intravenous cyclin-dependent kinase (CDK) 4/6 inhibitor, currently undergoing Phase 1b/2 trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. The company is also developing lerociclib, an oral CDK4/6 inhibitor, which is in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer. Additionally, G1 Therapeutics is progressing rintodestrant, an oral selective estrogen receptor degrader, currently in Phase I/2 trials. The company has partnered with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment in locally advanced breast cancer. G1 Therapeutics aims to improve treatment outcomes for cancer patients through its innovative therapeutic approaches.

ORIG3N

Series A in 2015
ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly affecting the heart, liver, and neurodegenerative conditions. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology, enabling the differentiation of cells into any type found in the body. This technology serves multiple purposes, including drug efficacy testing, medication toxicity screening, and facilitating personalized treatment approaches. The company's product offerings include LifeProfiles, a suite of genetic tests such as FITCODE, which provides insights into fitness-related traits; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

splitsecnd

Venture Round in 2015
splitsecnd is the only portable and effective portable plug-in vehicle connectivity device on the market. Designed to simply plug into the 12V lighter outlet in any car, splitsecnd can detect a crash, connect you to a live operator, send help to your location, and notify your emergency contact in an instant. Perfect for seniors, teens, and drivers of all ages, splitsecnd uses airbag sensor technology to activate the emergency response system on impact, calling for help even if you can’t respond; it can also be activated manually in the event of a 9-1-1 emergency or roadside breakdown. And with comprehensive trip analytics and GPS capabilities, splitsecnd lets you track routes, encourage good driving habits and even find your parked car. splitsecnd keeps up with you and your family on the road no matter where you are, what you drive, or what the situation. No cell phone required.

MedCenterDisplay

Series B in 2015
MedCenterDisplay offers a multifunctional network that helps healthcare organizations connect with patients in a robust way. They focus on providing healthcare marketers with turn-key solutions backed by engaging, creative content. The company's digital signage systems allow healthcare organizations to reach each and every person who walks through the door. Developed and tested by physicians and medical staff, MedCenterDisplay is an advanced digital communication network specifically designed to meet the needs of healthcare facilities. Their multi-functional network immediately engages patients and their families while they are waiting to see their healthcare provider.

Restore Medical Solutions

Series A in 2015
Restore Medical Solutions is a medical device company focusing on products and techniques that promote SSI reduction, safety, and productivity within healthcare. The company manufactures a sterilization tray system that reduces the risk of infection from contaminated medical instruments. Its modular sterilization tray systems reduce the potential risk of infection from contaminated instruments and enable surgical departments to improve the quality of care while reducing cost. Founded in 2012, Restore Medical Solutions is headquartered in Memphis, Tennessee.

Nusirt

Series C in 2015
NuSirt Sciences, Inc. is a biotechnology company based in Nashville, Tennessee, established in 2007. It focuses on developing innovative products for the prevention and treatment of metabolic diseases related to over-nutrition, such as obesity and type 2 diabetes. The company's technology platform combines natural compounds with pharmaceutical agents to activate sirtuin pathways, aiming to reduce the dosage of metformin, a standard treatment for early-stage type 2 diabetes, which some patients find difficult to tolerate due to side effects. NuSirt's lead product, NS-0100, combines leucine with a low dose of metformin and is currently undergoing Phase 2 clinical trials to determine its efficacy. The company has filed eleven patent applications, with two patents issued, and has conducted multiple pre-clinical and clinical studies to support its patented technologies. NuSirt has also formed strategic partnerships to enhance its research and development efforts in the field.

Myomo

Series B in 2015
Myomo, Inc. is a medical technology company based in Cambridge, Massachusetts, specializing in wearable medical robotics. Founded in 2004, Myomo develops myoelectric orthotics, particularly the MyoPro, a myoelectric-controlled upper limb brace designed to assist individuals with neuromuscular disorders, including those resulting from strokes, spinal cord injuries, and other neurological conditions. The MyoPro supports weak or paralyzed arms, facilitating daily activities at home and in the community. The company also offers the mPower 1000, a lightweight functional arm brace that aids in restoring movement, as well as a suite of therapeutic programs, including the PERL technique and myGames, which leverage virtual reality to enhance rehabilitation. Myomo's products are distributed through orthotics and prosthetics providers, rehabilitation hospitals, and the Veterans Health Administration, serving medical professionals, patients, and caregivers across the United States.

Contego Medical

Series B in 2015
Contego Medical, Inc. develops emboli protection devices that are used for the treatment of cardiovascular and endovascular diseases. It offers angioplasty balloons and stent delivery catheters, such as coronary stent systems, carotid post-dilation balloons, and renal artery stent systems with integrated embolic protection devices for enabling carotid, renal, SVG, and coronary interventions. Contego Medical, Inc. was formerly known as Contego Medical, LLC. The company was founded in 2005 and is based in Raleigh, North Carolina with an additional office in Curitiba, Brazil.

G1 Therapeutics

Series B in 2015
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. Founded in 2008, the company is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics is advancing several investigational therapies, including trilaciclib, an intravenous cyclin-dependent kinase (CDK) 4/6 inhibitor, currently undergoing Phase 1b/2 trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. The company is also developing lerociclib, an oral CDK4/6 inhibitor, which is in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer. Additionally, G1 Therapeutics is progressing rintodestrant, an oral selective estrogen receptor degrader, currently in Phase I/2 trials. The company has partnered with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment in locally advanced breast cancer. G1 Therapeutics aims to improve treatment outcomes for cancer patients through its innovative therapeutic approaches.

ORIG3N

Venture Round in 2015
ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly affecting the heart, liver, and neurodegenerative conditions. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology, enabling the differentiation of cells into any type found in the body. This technology serves multiple purposes, including drug efficacy testing, medication toxicity screening, and facilitating personalized treatment approaches. The company's product offerings include LifeProfiles, a suite of genetic tests such as FITCODE, which provides insights into fitness-related traits; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

Lineagen

Series C in 2015
Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002, the company offers a range of diagnostic tools, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental disorders, and NextStepDx PLUS, a genetic sequencing test for detecting small genomic alterations. Additionally, Lineagen provides M-CHAT.org, an online screening resource for developmental evaluation. The company focuses on improving outcomes for individuals with autism and other complex diseases by enabling early diagnosis and intervention. Lineagen's research capabilities are enhanced by its access to the Utah Population Database through the University of Utah, which supports significant discoveries in disease-related genetics. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Clearside Biomedical

Series B in 2014
Clearside Biomedical, Inc., a biopharmaceutical company, develops and delivers treatment that restore and preserve vision for people with serious eye diseases. Its preclinical products include CLS-AX, an axitinib for suprachoroidal injection. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.

MedCenterDisplay

Venture Round in 2014
MedCenterDisplay offers a multifunctional network that helps healthcare organizations connect with patients in a robust way. They focus on providing healthcare marketers with turn-key solutions backed by engaging, creative content. The company's digital signage systems allow healthcare organizations to reach each and every person who walks through the door. Developed and tested by physicians and medical staff, MedCenterDisplay is an advanced digital communication network specifically designed to meet the needs of healthcare facilities. Their multi-functional network immediately engages patients and their families while they are waiting to see their healthcare provider.

Castle Biosciences

Venture Round in 2014
Castle Biosciences, we focus on addressing this gap. We work with leading cancer institutions to in-license proprietary technologies and complete development and validation. The ultimate goal is to make these proven tests available to all individuals afflicted with a rare cancer.

InvisionHeart

Series A in 2014
InvisionHeart draws on the strengths of experienced leadership, robust software and hardware developers and a strong clinical advisory team. The technology was originally developed by a team of physicians and engineers at Vanderbilt University in response to real-world clinical problems. Along with their team of investors, they share a vision for the improved care of heart patients wherever they live and work.

Nusirt

Series B in 2014
NuSirt Sciences, Inc. is a biotechnology company based in Nashville, Tennessee, established in 2007. It focuses on developing innovative products for the prevention and treatment of metabolic diseases related to over-nutrition, such as obesity and type 2 diabetes. The company's technology platform combines natural compounds with pharmaceutical agents to activate sirtuin pathways, aiming to reduce the dosage of metformin, a standard treatment for early-stage type 2 diabetes, which some patients find difficult to tolerate due to side effects. NuSirt's lead product, NS-0100, combines leucine with a low dose of metformin and is currently undergoing Phase 2 clinical trials to determine its efficacy. The company has filed eleven patent applications, with two patents issued, and has conducted multiple pre-clinical and clinical studies to support its patented technologies. NuSirt has also formed strategic partnerships to enhance its research and development efforts in the field.

Nusirt

Series A in 2014
NuSirt Sciences, Inc. is a biotechnology company based in Nashville, Tennessee, established in 2007. It focuses on developing innovative products for the prevention and treatment of metabolic diseases related to over-nutrition, such as obesity and type 2 diabetes. The company's technology platform combines natural compounds with pharmaceutical agents to activate sirtuin pathways, aiming to reduce the dosage of metformin, a standard treatment for early-stage type 2 diabetes, which some patients find difficult to tolerate due to side effects. NuSirt's lead product, NS-0100, combines leucine with a low dose of metformin and is currently undergoing Phase 2 clinical trials to determine its efficacy. The company has filed eleven patent applications, with two patents issued, and has conducted multiple pre-clinical and clinical studies to support its patented technologies. NuSirt has also formed strategic partnerships to enhance its research and development efforts in the field.

Diagnovus

Seed Round in 2013
Diagnovus, founded in 2011 and located in Nashville, TN, specializes in molecular diagnostics aimed at rare cancers, including pediatric forms. The company is committed to developing innovative diagnostic tests that enhance the decision-making process for physicians, patients, and families dealing with challenging health conditions. By focusing on evidence-based products, Diagnovus aims to improve patient outcomes, support healthcare providers in delivering more effective care, and promote the efficient use of healthcare resources. Through its dedication to improving health and treatment quality, Diagnovus seeks to make a significant impact in the field of molecular diagnostics.

G1 Therapeutics

Series A in 2013
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. Founded in 2008, the company is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics is advancing several investigational therapies, including trilaciclib, an intravenous cyclin-dependent kinase (CDK) 4/6 inhibitor, currently undergoing Phase 1b/2 trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. The company is also developing lerociclib, an oral CDK4/6 inhibitor, which is in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer. Additionally, G1 Therapeutics is progressing rintodestrant, an oral selective estrogen receptor degrader, currently in Phase I/2 trials. The company has partnered with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment in locally advanced breast cancer. G1 Therapeutics aims to improve treatment outcomes for cancer patients through its innovative therapeutic approaches.

Diagnovus

Seed Round in 2013
Diagnovus, founded in 2011 and located in Nashville, TN, specializes in molecular diagnostics aimed at rare cancers, including pediatric forms. The company is committed to developing innovative diagnostic tests that enhance the decision-making process for physicians, patients, and families dealing with challenging health conditions. By focusing on evidence-based products, Diagnovus aims to improve patient outcomes, support healthcare providers in delivering more effective care, and promote the efficient use of healthcare resources. Through its dedication to improving health and treatment quality, Diagnovus seeks to make a significant impact in the field of molecular diagnostics.

ABT Molecular Imaging

Venture Round in 2013
ABT Molecular Imaging, based in Knoxville, Tennessee, specializes in medical imaging by designing, manufacturing, and marketing biomarker generator systems and related accessories. The company’s flagship product, the BG-75 Biomarker Generator, produces unit doses of molecular imaging drugs for positron emission tomography (PET) at the point of use, allowing for on-demand generation of PET biomarkers and radioisotopes. This innovative platform incorporates quality control tests and maintains dose records for each generated dose, ensuring high standards in medical imaging. Founded in 2006 by industry experts Ron and Lynda Nutt, ABT Molecular Imaging distributes its products through a global network of sales and service partners.

Streamweaver

Series A in 2013
Streamweaver is a software company located in Nashville, Tenn. The company's first product is a multi-angle mobile video app that automatically connects people to record together and then generates split-screen video.

SwingPal

Seed Round in 2013
SwingPal is a proprietary online golf lesson platform that connects golfers and instructors over the web and via mobile devices. Users record their swings with a smart phone, upload their videos instantly to a SwingPal account, and receive detailed and annotated video and audio analysis from a golf pro, as well as additional instructional videos.

Pathfinder Technologies

Venture Round in 2013
Pathfinder Technologies (formerly Pathfinder Therapeutics, Inc.), a medical device company, engages in the design, development, and manufacture of solutions in the field of navigated abdominal surgery. The company provides an integrated intra-operative image guidance system for open liver surgical procedure; and accessories, including IRED localization probes, navigated RF ablators, and navigated ultrasonic aspirators. Its system consists of a software architecture that allows the surgeon to display a 3D view of the liver. Its system is used in various open liver surgery applications, including hepatic resection, open ablation, open biopsy, living donor transplant, cyst removal, and tumor removal. Pathfinder Technologies was founded in 2004 and is based in Nashville, Tennessee.

Diagnovus

Seed Round in 2013
Diagnovus, founded in 2011 and located in Nashville, TN, specializes in molecular diagnostics aimed at rare cancers, including pediatric forms. The company is committed to developing innovative diagnostic tests that enhance the decision-making process for physicians, patients, and families dealing with challenging health conditions. By focusing on evidence-based products, Diagnovus aims to improve patient outcomes, support healthcare providers in delivering more effective care, and promote the efficient use of healthcare resources. Through its dedication to improving health and treatment quality, Diagnovus seeks to make a significant impact in the field of molecular diagnostics.

SwingPal

Seed Round in 2013
SwingPal is a proprietary online golf lesson platform that connects golfers and instructors over the web and via mobile devices. Users record their swings with a smart phone, upload their videos instantly to a SwingPal account, and receive detailed and annotated video and audio analysis from a golf pro, as well as additional instructional videos.

Pathfinder Technologies

Seed Round in 2013
Pathfinder Technologies (formerly Pathfinder Therapeutics, Inc.), a medical device company, engages in the design, development, and manufacture of solutions in the field of navigated abdominal surgery. The company provides an integrated intra-operative image guidance system for open liver surgical procedure; and accessories, including IRED localization probes, navigated RF ablators, and navigated ultrasonic aspirators. Its system consists of a software architecture that allows the surgeon to display a 3D view of the liver. Its system is used in various open liver surgery applications, including hepatic resection, open ablation, open biopsy, living donor transplant, cyst removal, and tumor removal. Pathfinder Technologies was founded in 2004 and is based in Nashville, Tennessee.

American Hometown Media

Seed Round in 2013
American Hometown Media, Inc. owns and operates an Internet platform to engage in analog publishing of American home cooks. The company syndicates the editorial content featuring journalism celebrating hometown cooks to community newspapers, magazines, and other media around the country. It also offers Just A Pinch Recipes, a digital recipe and coupon social network with a focus on home cooks; and Just A Pinch Syndicated Media, a platform to deliver content on home cooks, recipes, and snapshots of the culture and heritage of America's hometowns to media contacts. The company was founded in 2011 and is based in Nashville, Tennessee.

Diagnovus

Seed Round in 2013
Diagnovus, founded in 2011 and located in Nashville, TN, specializes in molecular diagnostics aimed at rare cancers, including pediatric forms. The company is committed to developing innovative diagnostic tests that enhance the decision-making process for physicians, patients, and families dealing with challenging health conditions. By focusing on evidence-based products, Diagnovus aims to improve patient outcomes, support healthcare providers in delivering more effective care, and promote the efficient use of healthcare resources. Through its dedication to improving health and treatment quality, Diagnovus seeks to make a significant impact in the field of molecular diagnostics.

Streamweaver

Series A in 2013
Streamweaver is a software company located in Nashville, Tenn. The company's first product is a multi-angle mobile video app that automatically connects people to record together and then generates split-screen video.

ABT Molecular Imaging

Series C in 2012
ABT Molecular Imaging, based in Knoxville, Tennessee, specializes in medical imaging by designing, manufacturing, and marketing biomarker generator systems and related accessories. The company’s flagship product, the BG-75 Biomarker Generator, produces unit doses of molecular imaging drugs for positron emission tomography (PET) at the point of use, allowing for on-demand generation of PET biomarkers and radioisotopes. This innovative platform incorporates quality control tests and maintains dose records for each generated dose, ensuring high standards in medical imaging. Founded in 2006 by industry experts Ron and Lynda Nutt, ABT Molecular Imaging distributes its products through a global network of sales and service partners.

Diagnovus

Seed Round in 2012
Diagnovus, founded in 2011 and located in Nashville, TN, specializes in molecular diagnostics aimed at rare cancers, including pediatric forms. The company is committed to developing innovative diagnostic tests that enhance the decision-making process for physicians, patients, and families dealing with challenging health conditions. By focusing on evidence-based products, Diagnovus aims to improve patient outcomes, support healthcare providers in delivering more effective care, and promote the efficient use of healthcare resources. Through its dedication to improving health and treatment quality, Diagnovus seeks to make a significant impact in the field of molecular diagnostics.

Streamweaver

Seed Round in 2012
Streamweaver is a software company located in Nashville, Tenn. The company's first product is a multi-angle mobile video app that automatically connects people to record together and then generates split-screen video.

Pathfinder Technologies

Venture Round in 2012
Pathfinder Technologies (formerly Pathfinder Therapeutics, Inc.), a medical device company, engages in the design, development, and manufacture of solutions in the field of navigated abdominal surgery. The company provides an integrated intra-operative image guidance system for open liver surgical procedure; and accessories, including IRED localization probes, navigated RF ablators, and navigated ultrasonic aspirators. Its system consists of a software architecture that allows the surgeon to display a 3D view of the liver. Its system is used in various open liver surgery applications, including hepatic resection, open ablation, open biopsy, living donor transplant, cyst removal, and tumor removal. Pathfinder Technologies was founded in 2004 and is based in Nashville, Tennessee.

SwingPal

Seed Round in 2012
SwingPal is a proprietary online golf lesson platform that connects golfers and instructors over the web and via mobile devices. Users record their swings with a smart phone, upload their videos instantly to a SwingPal account, and receive detailed and annotated video and audio analysis from a golf pro, as well as additional instructional videos.

MedCenterDisplay

Seed Round in 2012
MedCenterDisplay offers a multifunctional network that helps healthcare organizations connect with patients in a robust way. They focus on providing healthcare marketers with turn-key solutions backed by engaging, creative content. The company's digital signage systems allow healthcare organizations to reach each and every person who walks through the door. Developed and tested by physicians and medical staff, MedCenterDisplay is an advanced digital communication network specifically designed to meet the needs of healthcare facilities. Their multi-functional network immediately engages patients and their families while they are waiting to see their healthcare provider.

Nusirt

Seed Round in 2012
NuSirt Sciences, Inc. is a biotechnology company based in Nashville, Tennessee, established in 2007. It focuses on developing innovative products for the prevention and treatment of metabolic diseases related to over-nutrition, such as obesity and type 2 diabetes. The company's technology platform combines natural compounds with pharmaceutical agents to activate sirtuin pathways, aiming to reduce the dosage of metformin, a standard treatment for early-stage type 2 diabetes, which some patients find difficult to tolerate due to side effects. NuSirt's lead product, NS-0100, combines leucine with a low dose of metformin and is currently undergoing Phase 2 clinical trials to determine its efficacy. The company has filed eleven patent applications, with two patents issued, and has conducted multiple pre-clinical and clinical studies to support its patented technologies. NuSirt has also formed strategic partnerships to enhance its research and development efforts in the field.

Diabetes Care Group

Venture Round in 2012
Diabetes Care Group, Inc. provides diabetes clinical care services for individuals with diabetes. It offers medical management, patient education and personalized counseling, behavioral modification, diet and nutrition, specialized medical treatment, blood glucose monitoring, point-of-care laboratory, and data management services to improve patient self-management and clinical outcomes. Diabetes Care Group, Inc. was formerly known as Diabetes Care Associates, Inc. The company was founded in 1986 and is based in Jackson, Mississippi. Diabetes Care Group, Inc. operates as a subsidiary of Renal Care Group, Inc.

OnFocus Healthcare

Venture Round in 2012
Originally founded in 1985 as a healthcare strategic planning consulting firm called m21partners, onFocus Healthcare was re-incorporated in 2008 as a business execution software solutions company. Today, onFocus is the leading provider of enterprise performance management (EPM) software and support services for the healthcare marketplace. Their product, onFocus epm™, ensures that patients get better, faster, and less expensive care by helping hospitals continuously execute and perform at higher levels. They are dedicated to the success of healthcare organizations and the executives, managers and employees who lead them. Through the use of their software products and advisory services, they strive to improve the execution success and performance of every provider they work with by at least 20%.

Pathfinder Technologies

Seed Round in 2012
Pathfinder Technologies (formerly Pathfinder Therapeutics, Inc.), a medical device company, engages in the design, development, and manufacture of solutions in the field of navigated abdominal surgery. The company provides an integrated intra-operative image guidance system for open liver surgical procedure; and accessories, including IRED localization probes, navigated RF ablators, and navigated ultrasonic aspirators. Its system consists of a software architecture that allows the surgeon to display a 3D view of the liver. Its system is used in various open liver surgery applications, including hepatic resection, open ablation, open biopsy, living donor transplant, cyst removal, and tumor removal. Pathfinder Technologies was founded in 2004 and is based in Nashville, Tennessee.

Industrial Ceramic Solutions

Seed Round in 2011
Industrial Ceramic Solutions, LLC develops and manufactures air pollution control equipment for industrial and diesel exhaust filter applications. It offers diesel particulate and exhaust, high-temperature exhaust, air and gas, and odor and smoke control and elimination filers; and particulate matter filter cartridges. The company was incorporated in 1997 and is based in Oak Ridge, Tennessee.

Diagnovus

Seed Round in 2011
Diagnovus, founded in 2011 and located in Nashville, TN, specializes in molecular diagnostics aimed at rare cancers, including pediatric forms. The company is committed to developing innovative diagnostic tests that enhance the decision-making process for physicians, patients, and families dealing with challenging health conditions. By focusing on evidence-based products, Diagnovus aims to improve patient outcomes, support healthcare providers in delivering more effective care, and promote the efficient use of healthcare resources. Through its dedication to improving health and treatment quality, Diagnovus seeks to make a significant impact in the field of molecular diagnostics.

Panopto

Venture Round in 2011
Panopto helps businesses and universities create searchable video libraries of their institutional knowledge. Since 2007, the company has been a pioneer in video capture software, video content management systems, and inside-video search technology. Today, Panopto’s video platform is the largest repository of expert learning videos in the world. Headquartered in Seattle with offices in Pittsburgh, London, Hong Kong, Beijing, and Sydney, Panopto has received industry recognition for its innovation, rapid growth, and company culture.

OnFocus Healthcare

Series B in 2010
Originally founded in 1985 as a healthcare strategic planning consulting firm called m21partners, onFocus Healthcare was re-incorporated in 2008 as a business execution software solutions company. Today, onFocus is the leading provider of enterprise performance management (EPM) software and support services for the healthcare marketplace. Their product, onFocus epm™, ensures that patients get better, faster, and less expensive care by helping hospitals continuously execute and perform at higher levels. They are dedicated to the success of healthcare organizations and the executives, managers and employees who lead them. Through the use of their software products and advisory services, they strive to improve the execution success and performance of every provider they work with by at least 20%.